Oculis (OCS)
Develops investigational therapies for neuro-ophthalmology and dry eye disease.
$10.14
vs last close−0.57 (−5.32%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 43 days
EPS estimate
−$0.49
Revenue estimate
$263.2K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.76−$0.77−$0.59−$0.40−$0.51−$0.63−$0.20Pending
Estimate−$0.48−$0.51−$0.53−$0.50−$0.48−$0.49−$0.48−$0.49
Surprise−58.3%−51.0%−11.3%+20.0%−6.7%−28.6%+58.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$3.3K$321.9K$328.5K$305.5K$518.4K$250.3K$383.5KPending
Estimate$144.2K$217.5K$143.3K$136.9K$142.9K$253.8K$216.8K$263.2K
Surprise−97.7%+48.0%+129.2%+123.2%+262.8%−1.4%+76.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.42 | — | — |
| Sep 2027 | −$0.41 | — | — |
| Jun 2027 | −$0.39 | — | — |
| Mar 2027 | −$0.39 | — | — |
| Dec 2026 | −$0.43 | — | — |
| Nov 2026 | −$0.49 | — | — |
| Aug 2026 | −$0.48 | −$0.20 | +58.3% |
| May 2026 | −$0.49 | −$0.63 | −28.6% |
| Mar 2026 | −$0.48 | −$0.51 | −6.7% |
| Nov 2025 | −$0.50 | −$0.40 | +20.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Mar 2023 | |||
| Mar 2023 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.42 | — | — | $99.8K | — | — | — |
| Sep 2027 | −$0.41 | — | — | $99.8K | — | — | — |
| Jun 2027 | −$0.39 | — | — | $99.8K | — | — | — |
| Mar 2027 | −$0.39 | — | — | $99.8K | — | — | — |
| Dec 2026 | −$0.43 | — | — | $209.9K | — | — | — |
| Nov 5, 2026 | −$0.49 | — | — | $263.2K | — | — | — |
| Aug 6, 2026 | −$0.48 | −$0.20 | +58.3% | $216.8K | $383.5K | +76.9% | +2.4% |
| May 11, 2026 | −$0.49 | −$0.63 | −28.6% | $253.8K | $250.3K | −1.4% | +0.0% |
| Mar 3, 2026 | −$0.48 | −$0.51 | −6.7% | $142.9K | $518.4K | +262.8% | −3.6% |
| Nov 10, 2025 | −$0.50 | −$0.40 | +20.0% | $136.9K | $305.5K | +123.2% | +1.0% |
| Aug 21, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 11, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 27, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 18, 2024 | |||||||
| Nov 15, 2023 | |||||||
| Aug 29, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Mar 28, 2023 | |||||||
| Sep 30, 2022 | |||||||
| Jun 30, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Dec 31, 2021 | |||||||
| Sep 30, 2021 |